Merck, in turn, points out that its older technology is tried and true, while Glaxo's is still relatively untested.

FORBES

The article also looks at whether those works could be potentially a better buy than those by relatively untested young artists, who after the first wave of buying and speculation, could see prices for their works slump.

FORBES: Art Prices: What Goes Up Can Also Come Down